Quintiles and Quest Diagnostics to Form Joint Venture
Quintiles and Quest Diagnostics announced a definitive agreement to form a global clinical trials laboratory services business.
Quintiles and Quest Diagnostics announced a definitive agreement to form a global clinical trials laboratory services business. The new entity will provide customers with the depth of capabilities and end-to-end clinical trial laboratory services and becomes the second-largest central laboratory services company operating globally. Upon closing of the transaction, Quintiles will own 60% and Quest Diagnostics will own 40% of the new joint venture.
The new entity also will leverage a number of additional resources including Quest Diagnostics draws from 20 billion test results, and Quintiles’ assets include electronic health records representing more than 60 million patient lives and a network of 250,000 clinical investigators.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025